Oxford BioMedica Limited

About Oxford BioMedica Limited

Oxford BioMedica Limited is a leading gene and cell therapy company based in the UK, renowned for its innovative approach to developing advanced therapies for serious diseases. The company specializes in the development of viral vector-based therapies, particularly focusing on the treatment of cancer, neurological disorders, and rare diseases.

Founded in 1995, Oxford BioMedica has established itself as a pioneer in the field of gene therapy, leveraging its proprietary LentiVector® platform to create transformative treatments. The company collaborates with various pharmaceutical and biotechnology partners to advance its therapeutic candidates through clinical trials and into the market.

With a strong commitment to research and development, Oxford BioMedica invests significantly in cutting-edge technologies and facilities to enhance its capabilities in gene and cell therapy. The company’s vision is to improve patient outcomes by providing effective and accessible therapies that address unmet medical needs.

• Core Activities: Development of gene and cell therapies, clinical trials, and partnerships with industry leaders.
• Vision: To be at the forefront of gene therapy innovation, improving lives through advanced medical solutions.
• Commitment: Focused on research, collaboration, and delivering high-quality therapies to patients.

Oxford BioMedica is headquartered in Oxford, UK, and continues to expand its global presence in the biopharmaceutical sector. The company is dedicated to fostering a culture of excellence and integrity, ensuring that its operations align with the highest ethical standards.